Figure 2From: Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy) Study design. Figure legend text: KPS, Karnowsky Performance Status; Crea, Creatinine; ULN, upper limit of normal (> 1.1 mg/dl for men and > 0.9 mg/dl for women); GFFC, combination of gemcitabine, 5-fluorouracil, folinic acid and cisplatin; GEM, gemcitabine monotherapy; PD, partial remission; CR, complete remission.Back to article page